Jump to Navigation
Home

Main menu

  • Home
  • Latest Stories
  • Markets Map
  • Trends and Sentiments
  • Leading Topics
  • News Search
  • Comments and Analysis

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • About Us
  • Is Your Credit Card Less Secure Than Ever Before?
  • Glacier Bancorp's (GBCI) CEO Randall Chesler on Q1...
  • Chemed's (CHE) CEO Kevin McNamara on Q1 2018 Results...
  • Trade war 'extremely dangerous' for global...
  • US said to investigate AT&T and Verizon over wireless...
  • Picture-perfect forgery? Art world awaits court decision...
  • ‘Eat SHYTE’: How this Ontario man’s chocolate brand...
  • Sergio Garcia lost his cool after a bad shot and threw...
  • Come see Henry Blodget break down VR, AR, and AI at the...
  • What are the odds an ex-fighter pilot like Capt. Tammie...

    Arena’s Lorqess: A Market Size Analysis

    Tue, 09/14/2010 - 05:53 EDT - Seeking Alpha
    • ARNA
    • OREX
    • Rockford Coscia
    • VVUS

    Rockford Coscia submits: The week has finally arrived. This Thursday an FDA advisory panel will take on one of the most controversial drugs of recent memory. Arena’s (ARNA) Lorqess, also known as lorcaserin, will be evaluated ultimately on whether its benefits outweigh its side effects. I’ve written other articles about Lorqess’ valvulopathy “issue” and its odds of passing based on the Qnexa panel, but today I wanted to tackle the share price issue on approval by the FDA. My hopes are that this analysis will help readers to have a better understanding of where share prices should rest upon favorable panel review and ultimately if and when approval is gained. Let me start by saying that the potential sales estimation, and therefore underlying share price, is one of the most difficult estimations I’ve seen for biotechs. This seems largely due to the fact that, while obesity is a tremendously large potential market, it is grossly under treated. A statistician might say that the error bars associated with this sort of valuation are astronomically huge. Use the information presented here and elsewhere and come up with a figure you believe in and invest accordingly. Other attempts at this analysis have been presented here, here, and here.Complete Story »

    • Original article
    • Login to post comments
     

    Related

    • Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors

      Rockford Coscia submits:

    • A Future for Arena's Diet Pill? Fat Chance

      Pharmalot submits: After meeting with FDA officials to review the recent rejection of its Lorqess diet pill, Arena Pharmaceuticals (ARNA) now plans to refile its application by the end of 2011.

    • Lorcaserin’s Path to Approval

      KLLJ Investments submits: On Friday, October 22nd, Arena Pharmaceuticals (ARNA) finally learned the path forward for approval of Lorcaserin for weight loss. This came in the form of a Complete Response Letter (CRL) from the FDA. The last analysis I read showed that only around 30% of drugs are approved by the FDA on the initial NDA review so it isn’t a surprise that Arena receive

    • The Upcoming Verdict on Arena's Obesity Drug

      Prohost Biotech submits:This Thursday an FDA advisory panel will discuss Arena’s (ARNA) drug Lorqess (lorcaserin) for obesity.

    • Arena's Lorcaserin: Weighed Down by Qnexa and Meridia

      Joseph Krueger submits: Before the FDA review panel’s of Vivus’s (VVUS) drug Qnexa, I expressed significant doubt that the panel review would be positive based primarily on the safety issues surrounding one of its ingredients topiramate here.

    • EnteroMedics (ETRM) Obesity Device Gets FDA Approval

      Yesterday EnteroMedics Inc (NASDAQ:ETRM), received the US Food and Drug Administration’s (FDA) approval for its weight loss device, Maestro. The announcement also resulted in an 18% increase in its stock price. This is the FDA’s first approval for an obesity device after 2007.

    • Arena's Weight Loss Drug Receives FDA Advisory Panel Recommendation For Approval

      By Scott Matusow:Today, an FDA advisory panel voted 18-4 to recommend approval of lorcaserin, developed by Arena Pharma (ARNA). The panel concluded that its benefits "outweigh the potential risks when used long term" in overweight and obese people. One panel member abstained from voting.

    • Vivus' Qnexa Panel Bodes Well for Arena's Obesity Drug

      Rockford Coscia submits:This post is a long one but I promise it’s worthwhile for the Arena (ARNA) crowd.

    • Preview Of Arena's Upcoming Advisory Committee

      By KLLJ Investments: On the morning of May 8th, the Food & Drug Administration (FDA) will release the briefing documents for the May 10th Advisory Committee (AdCom) meeting to discuss the risk and benefit profile of Arena Pharmacueticals' (ARNA) new drug, Lorqess (lorcaserin hydrochloride).

    • Arena’s Diet Pill May Encounter Yet Another Issue: Heart Valve Disease

      Pharmalot submits: When the FDA issued a complete response letter last month for the Arena Pharmaceutical (ARNA) diet pill, the agency cited a few reasons: pending results of a trial in 604 patients with diabetes, concerns that the pill may cause tumors in rats and efficacy was marginal (look here).

    Latest

    Picture-perfect forgery? Art world awaits court decision on alleged Norval Morrisseau fraud ring
    Picture-perfect forgery? Art world awaits court...
    ‘Eat SHYTE’: How this Ontario man’s chocolate brand became famous in the U.K.
    ‘Eat SHYTE’: How this Ontario man’s chocolate...

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 2579.37 0.16% FTSE: 7487.96 -0.07% Nikk.: 22420.08 1.82% DAX: 13465.51 1.75% HSI: 28594.06 1.22% FX: EUR/GBP: 1.1401 USD/EUR: 1.1618 JPY/USD: 114.1510 Commodities: Gold: 1276.1000

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • About Us